Zacks: Brokerages Anticipate Boston Scientific Co. (BSX) Will Post Quarterly Sales of $2.56 Billion

Brokerages expect Boston Scientific Co. (NYSE:BSX) to announce sales of $2.56 billion for the current quarter, Zacks Investment Research reports. Eight analysts have made estimates for Boston Scientific’s earnings, with the lowest sales estimate coming in at $2.55 billion and the highest estimate coming in at $2.57 billion. Boston Scientific posted sales of $2.41 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 6.2%. The firm is scheduled to announce its next earnings report on Thursday, February 7th.

According to Zacks, analysts expect that Boston Scientific will report full year sales of $9.83 billion for the current financial year, with estimates ranging from $9.81 billion to $9.88 billion. For the next fiscal year, analysts anticipate that the business will post sales of $10.64 billion, with estimates ranging from $10.53 billion to $10.86 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Boston Scientific.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, October 24th. The medical equipment provider reported $0.35 EPS for the quarter, topping the Zacks’ consensus estimate of $0.34 by $0.01. Boston Scientific had a return on equity of 26.44% and a net margin of 6.93%. The company had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.40 billion. During the same period last year, the firm earned $0.31 EPS. Boston Scientific’s revenue for the quarter was up 7.7% compared to the same quarter last year.

A number of research firms have commented on BSX. BTIG Research reissued a “buy” rating and set a $45.00 price target on shares of Boston Scientific in a report on Tuesday, October 16th. Oppenheimer set a $38.00 price target on Boston Scientific and gave the company a “hold” rating in a report on Wednesday, October 24th. Canaccord Genuity raised their price target on Boston Scientific from $40.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, October 25th. Royal Bank of Canada raised their price target on Boston Scientific to $36.00 and gave the company a “top pick” rating in a report on Monday, July 23rd. Finally, Morgan Stanley raised their price target on Boston Scientific from $38.00 to $48.00 and gave the company an “overweight” rating in a report on Tuesday, October 2nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have issued a buy rating and three have assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $39.00.

In other Boston Scientific news, EVP David A. Pierce sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $36.02, for a total transaction of $180,100.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP John Bradley Sorenson sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $35.86, for a total value of $358,600.00. Following the transaction, the senior vice president now owns 44,636 shares of the company’s stock, valued at approximately $1,600,646.96. The disclosure for this sale can be found here. Insiders have sold 414,000 shares of company stock valued at $15,347,937 in the last 90 days. Company insiders own 0.73% of the company’s stock.

Several large investors have recently made changes to their positions in the business. Sei Investments Co. raised its stake in shares of Boston Scientific by 7.8% during the second quarter. Sei Investments Co. now owns 3,853,853 shares of the medical equipment provider’s stock valued at $126,021,000 after acquiring an additional 278,777 shares in the last quarter. Waddell & Reed Financial Inc. bought a new stake in shares of Boston Scientific during the second quarter valued at approximately $5,559,000. Cubist Systematic Strategies LLC raised its stake in shares of Boston Scientific by 3.1% during the second quarter. Cubist Systematic Strategies LLC now owns 51,105 shares of the medical equipment provider’s stock valued at $1,671,000 after acquiring an additional 1,547 shares in the last quarter. Public Employees Retirement System of Ohio raised its stake in shares of Boston Scientific by 2.0% during the second quarter. Public Employees Retirement System of Ohio now owns 965,855 shares of the medical equipment provider’s stock valued at $31,583,000 after acquiring an additional 19,383 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its stake in shares of Boston Scientific by 63.6% during the second quarter. Nisa Investment Advisors LLC now owns 319,940 shares of the medical equipment provider’s stock valued at $10,462,000 after acquiring an additional 124,350 shares in the last quarter. Institutional investors and hedge funds own 91.24% of the company’s stock.

NYSE:BSX traded up $0.78 on Friday, reaching $37.63. 310,466 shares of the company’s stock traded hands, compared to its average volume of 8,830,114. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.58. The stock has a market cap of $50.94 billion, a PE ratio of 29.87, a P/E/G ratio of 2.42 and a beta of 0.68. Boston Scientific has a 12 month low of $24.54 and a 12 month high of $39.44.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Featured Story: Index Funds

Get a free copy of the Zacks research report on Boston Scientific (BSX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply